Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 132952Generated: October 30, 2026

4-Methylmorpholine → (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4S)-4-phenoxypyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide

https://huagongshe.com/reaction/132952

Reaction equation

Participants

RoleNameHCIDCharge
Reactant4-MethylmorpholineHCID 7972—
ReactantMethanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 9886157—
Reactant(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-4-phenylbutanoic acidHCID 67270863—
Reactant(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((2R,4S)-1-benzhydryl-4-phenoxypyrrolidin-2-yl)-3-(3,5-difluorophenyl) 1-hydroxypropan-2-yl)-4-phenylbutanamideHCID 69193948—
Reactant(1S,2S)-2-amino-1-((2R,4S)-1-benzhydryl-4-phenoxypyrrolidin-2-yl)-3-(3,5-difluorophenyl)propan-1-olHCID 69195486—
SolventDimethylformamideHCID 6228—
Product(S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4S)-4-phenoxypyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamideHCID 69196467—

Reaction Steps

Step 9 (C): (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((2R,4S)-1-benzhydryl-4-phenoxypyrrolidin-2-yl)-3-(3,5-difluorophenyl)-1-hydroxypropan-2-yl)-4-phenylbutanamide. To a solution of (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-4-phenylbutanoic acid (Preparation A, 29 mg, 0.080 mmol) in DMF (2 mL) was added HATU (36.5 mg, 0.096 mmol). A solution of (1S,2S)-2-amino-1-((2R,4S)-1-benzhydryl-4-phenoxypyrrolidin-2-yl)-3-(3,5-difluorophenyl)propan-1-ol (Step 9 (B), 41.1 mg, 0.080 mmol) in DMF (2 mL) was then added, followed by N-methylmorpholine (37 μl, 0.336 mmol). The reaction mixture was stirred at rt for 3 h. pH 4 buffer was then added to quench. The mixture was extracted with ethyl acetate. The organic phase was washed with sat. aqueous NaCl, dried (MgSO4), and concentrated in vacuo. The crude mixture was purified by reverse phase Prep HPLC to give the title compound (34 mg): 1H NMR (CDCl3, 300 MHz) δ 0.82 (3H, d, J=6 Hz), 0.98 (3H, m), 1.07-1.15 (1H, m), 1.51-1.61 (1H, m), 1.68-1.74 (1H, m), 1.85-2.08 (5H, m), 2.17-2.30 (1H, m), 2.41-2.57 (2H, m), 2.63-2.76 (2H, m), 2.80-2.95 (3H, m), 3.09 (1H, dd, J=3, 15 Hz), 3.47-3.54 (3H, m), 3.67-4.05 (6H, m), 5.08 (1H, m), 5.39 (1H, s), 5.99 (1H, s), 6.56-6.69 (4H, m), 6.86 (2H, d, J=9 Hz), 7.03 (1H, m), 7.14-7.34 (12H, m), 7.68 (2H, m), 7.63-7.66 (2H, m). HPLC retention time: 1.99 min (method C). MS (ESI) (M+H)+ 857.45.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07388007B2
Source datasetuspto-grants-2008_06
ORD IDord-41d088f1b94c43db9e0c44bbd42f04f5
Source noteuspto-grants-2008_06